SAN DIEGO, April 10 /PRNewswire/ -- MedImmune today announced that
researchers will present seven abstracts on the company's oncology portfolio
programs at the Annual Meeting of the American Association for Cancer
Research, exemplifying the company's long-standing commitment to excellence in
"Cancer research has long been a core area of focus at MedImmune and we
are proud to share data from our increasingly large oncology portfolio at this
year's meeting," said Bahija Jallal, Ph.D., vice president of translational
science and head, preclinical oncology.
Investigators will present results from four studies of the novel heat
shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride (also known as
IPI-504); two studies of antibodies targeting the CD19 antigen, including
MEDI-538 (also known as MT103); and one study of monocyte chemotactic
MedImmune research scheduled to be presented includes:
-- IPI-504, a Novel Hsp90 Inhibitor is Effective in EGFR T790M and
non-T790M Gefitinib-Resistant Lung Cancer Cell Lines (Oral
Presentation: Histone Deacetylase and Heat Shock Protein Inhibitors,
abstract 2450) - Joon O. Park, M.D., Monday, April 14 from 11:55 a.m.
- 12:10 p.m. in Room 24A-C.
-- Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of
17-AAG and Potent Inhibitor of Hsp90 (Educational Session: From
Chemistry to the Clinic: Pathways for Drug Discovery and Development
- Part 4: Chemical Development: Translating a Potent Agent into a
Registered Product) - James R. Porter, Ph.D., Saturday, April 12 from
4:15 - 4:40 p.m. in Ballroom 20D.
-- IPI-504, a Selective Inhibitor of Hsp90, Exhibits Potent Anti-Tumor
Activity Against Metastatic Melanoma Cell Lines that Harbor B-Raf or
N-Ras Mutations (Poster Session: Pharmacology and Pharmacodynamics,
abstract 4764, poster section 28, board 9) - Jon Cheesebrough, Tuesday,
April 15 from 1:00 - 5:00 p.m. in Exhibit Hall B-F.
-- IPI-504, a Selective Hsp90 Inhibitor is Biologically Active and
Tolerated in Combination with Trastuzumab in Preclinical Models of HER2
Positive Tumor Xenografts (Poster Session: Drug Discovery 2:
Combination Strategies I, abstract 4008, poster section 29, board 6)
- Ching Ching Leow, Ph.D., Tuesday, April 15 from 8:00 a.m. - 12:00
p.m. in Exhibit Hall B-F.
-- Bioavailability, Pharmacodynamic Activity, and Anti-Tumor Efficacy of
the CD19/CD3-Specific BiTE Antibody MEDI-538 (MT103) Delivered
Subcutaneously in Animal Models (Poster Session: Antibodies and
Immunotherapy, abstract 2131, poster section 23, board 6) - Kathy
Mulgrew, Monday, April 14 from 8:00 a.m. - 12:00 p.m. in Exhibit Hall
-- Inhibition of Growth of Human Lymphoma Xenografts with a
Glycoengineered Antibody Specific for the B-Cell Antigen CD19 (Poster
Session: Antibodies and Immunotherapy, abstract 3980, poster section
28, board 8) - Beth K. Ward, Tuesday, April 15 from 8:00 a.m. - 12:00
p.m. in Exhibit Hall B-F.
-- The Characterization of a Potent, Fully Human MCP-1 Antibody In Vitro
and In Vivo (Poster Session: Antibodies, abstract 3986, poster section
28, board 14) - Z. Alexander Cao, Ph.D., Tuesday, April 15 from 8:00
a.m. - 12:00 p.m. in Exhibit Hall B-F.
MedImmune strives to provide better medicines to patients, new medical
options for physicians and rewarding careers to employees. Dedicated to
advancing science and medicine to help people live better lives, the company
is focused on cardiovascular/gastrointestinal disease, neuroscience, oncology,
infection, respiratory disease and inflammation. With approximately 3,000
employees worldwide and headquarters in Maryland, MedImmune is wholly owned by
AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit
MedImmune's website at www.medimmune.com.
Jamie Lacey, +1-301-398-4035
both of MedImmune
Web site: http://www.medimmune.com